Türkiye’de boğmaca epidemiyolojisi: Pekiştirme aşı dozları gerekli mi?

Amaç: Türkiye’de, 1968 yılından beri, bebeklere yaşamın ilk yılında üç doz (2, 3 ve 4.ayda) ve 16-24 aylık iken rapel doz olacak şekilde rutin boğmaca aşısı yapılmaktadır. 2007’den beri, boğmaca aşısı aselüler aşı şekilde uygulanmaktadır. Son yıllarda artan aşı oranları ile birlikte ülkemizde boğmaca insidansında önemli bir azalma olmuştur. 1970’li yıllarda %20-30 olan 3 doz DBT aşı oranları, 2005 yılına gelindiğinde %90’a ulaşmıştır. Buna parelel olarak, 1970’li yıllarda 100.000’de 21 olan boğmaca insidansı 2005 yılında 100.000’de 0.38’e düşmüştür. Sağlık Bakanlığı verilerine göre, Doğu Bölgelerimiz dışında Dünya Sağlık Örgütü’nün hedeflediği insidansa (

Pertussis epidemiology in Turkey: Are booster doses necessary?

Aim: In Turkey, routine childhood pertussis immunization with whole cell pertusis vaccine (DTP) has been given since 1968. Pertussis vaccine has been administered in the 2nd, 3rd, and 4th months of life, in combination with a booster dose administered between the 16th and 24th months. Acellular pertussis vaccine has been administered since 2007. It is observed that vaccination coverage rates steadily increased and pertussis incidence decreased by years( with time? over the years?). Third-dose DTP vaccination coverage increased from 1970 (20&#8211;30%) to 2005 (90%). In 2005, pertussis incidence tended to decrease (0.38 per 100.000) compared to 1970 (21 per 100.000). According to the available data of the Ministry of Health, Turkey appears to be reaching the WHO target, with a pertussis incidence of <1 case per 100.000, except for East Anatolia. However, pertussis still affects all age groups, especially adolescents, adults, and young infants in Turkey, and occurs endemically with 2- to 5-year cycles of increased disease incidence. It was noticed that the number of cases increased in 1997 and 2004 despite increased coverage. The incidence of reported pertussis among adolescents and adults has increased over the past decade in our country. Even though only up to 6.5% of the cases were &#8805;15 years of age until 2005, 16.9% of them were included in this age group in 2005. Consequently, the four doses of infant pertusis vaccination administered in Turkey is not sufficient for longlasting protection against the infection. A large number of schoolchildren, adolescents, and adults are susceptible to pertusis infection, and therefore improvement in vaccination procedures in our country is necessary. Booster doses of pertussis vaccine for pre-school children and adolescence might be considered. (

Kaynakça

1. Versteegh FGA, Schellekens JFP, Fleer A, Roord JJ. Pertussis: a concise historical review including diagnosis, incidence, clinical manifestations and the role of treatment and vaccination in management. Rev Med Microbiol 2005; 16: 79-89.

2. Wood N, Mclntyre P. Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatr Respir Rev 2008; 9: 201-2.

3. Cherry DJ. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005; 115: 1422-7.

4. Aksakal F, Coplu N, Ceyhan M, Sonmez C, Ozkan S, Esen B, Ilhan M, Aygun R. High incidence of pertussis among schoolchildren with prolonged cough in Turkey. Tohoku J Exp Med 2007; 211: 353-8.

5. Yıldırım I, Ceyhan M, Kalaycı O, et al. Frequency of pertussis in children with prolonged cough. Scand J Infect Dis 2008; 40: 314-9.

6. Cherry DJ, Grimprel E, Guiso N, et al. Defining pertussis epidemiology. Pediatr Infect Dis J 2005; 24: 25-35.

7. WHO. Vaccine- preventable diseases:monitoring system global summary (2007). www-nt.who.int/vaccines/globalsummary/Immunization/CountryProfileSelect.cfm. 8. Long SS, Edwards KM: Bordetella pertussis (pertussis) and other species. Long SS, Pickering LK, Prober CG (eds). Principles and Practice of Pediatric Infectious Diseases; s.880-8, New York: Churchill Livingstone (2003).

9. Centers for Disease Control and Prevention: Pertussis-United States, 1997-2000. MMWR 2002; 51: 73-6.

10. KondaT, Kamachi K, Iwaki M, Matsunaga Y. Distrubution of pertussis antibodies among different age groups in Japan. Vaccine 2002; 20: 1711-7.

11. Van der Wielen M, Van Damme P, Van Herck K, Schlegel-Haueter S, Siegrist CA. Seroprevalence of Bordetella pertussis antibodies in Flanders (Belgium). Vaccine 2003; 21: 2412-7.

12. Tan T, Trindade E, Skowronski D. Epidemiology of Pertussis. Pediatr Infect Dis 2005; 24: 10-8.

13. Andrews R, Herceg A, Roberts C. Pertussis notifications in Australia 1991 to 1997. Commun Dis Intell 1997; 21: 145-8.

14. Dilli D, Bostanci I, Dallar Y, Buzgan T, Irmak H, Torunoglu MA. Recent findings on pertussis epidemiology in Turkey. Eur J Clin Infect Dis 2008; 27: 335-41.

15. Esen B, Coplu N, Kurtoglu D, Gozalan A, Akin L. Prevalence of high antibody titers of pertussis in Turkey: reflection of circulating microorganism and a threat to infants. Journal of Clinical Laboratory Analysis 2007; 21: 154-61.

16. Çöplü N, Nar S, Efsun A, Kurtoglu D, Esen B. A field survey carried out on the confirmation of a pertussis case in a village of Kırıkkale Province, Turkey. Mikrobiyol Bul 2007; 41: 175-83.

17. http://data.euro.who.int/CISID/

18. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005; 24: 858-61.

19. Ozkan S, Aksakal FN, Tuzun H, Aycan S, Maral I. Bordetella pertussis seroprevalence among vaccinated school children in Ankara, Turkey. Infection 2007; 35: 387-9.

20. Vatansever Ü, Çöplü N, Öner N, Sönmez C, Karasalihoglu S, Kurtoglu D, Esen B, Ekuklu G. Seroprevalance of Bordetella pertussis antibodies among healthy adolescent girls in Edirne. Swiss Med Wkly 2005; 135: 531-6.

21. www.saglık.gov.tr

Kaynak Göster